Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial

Documenti analoghi

• Efficacy and safety of continuous glucose monitoring on glycaemic control in patients with chronic pancreatitis and insulin‐treated diabetes: A randomised, open‐label, crossover trial
  di: Line Davidsen, et al.
  Pubblicazione: (2025)
• Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials
  di: Domenica Rubino, et al.
  Pubblicazione: (2024)
• Slowing the progression of diabetic and non‐diabetic kidney disease: A summary of the current evidence base for sodium‐glucose co‐transporter‐2 inhibitors
  di: Viktor Rotbain Curovic, et al.
  Pubblicazione: (2024)
• Monlunabant in adults with obesity and metabolic syndrome: Open‐label extension of a phase 2a trial
  di: Filip K. Knop, et al.
  Pubblicazione: (2026)
• Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
  di: Jason M. Samuels, et al.
  Pubblicazione: (2025)